The VR-DCEP regimen rescues mobilization failures and controls refractory disease in multiple myeloma

Affiliations

¹ Division of Hematology and Blood & Marrow Transplant, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA. maxwell.krem@uky.edu.
² James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA.
³ Department of Biostatistics, College of Public Health and Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA.
⁴ Geisinger Medical Center, Danville, PA, USA.
⁵ Division of Hematology and Blood & Marrow Transplant, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA.

Maxwell M Krem et al. Bone Marrow Transplant. 2020 Jul.

. 2020 Jul;55(7):1451-1453.

doi: 10.1038/s41409-019-0735-6. Epub 2019 Nov 8.

¹ Division of Hematology and Blood & Marrow Transplant, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA. maxwell.krem@uky.edu.
² James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA.
³ Department of Biostatistics, College of Public Health and Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA.
⁴ Geisinger Medical Center, Danville, PA, USA.
⁵ Division of Hematology and Blood & Marrow Transplant, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA.

No abstract available

References

1. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al. American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and international myeloma working group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transpl. 2015;21:2039–51. - DOI
1. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transpl. 2014;20:295–308. - DOI
1. Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transpl. 2001;28:835–9. - DOI
1. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176–85. - DOI
1. Beyer K, Rosner S, Woo KM, Devlin SM, Landau H, Hassoun H, et al. Analysis of VDT-PACE utilization in multiple myeloma patients treated at MSKCC for relapsed disease or cytoreduction and stem cell mobilization after initial induction therapy. Blood. 2014;124:3459. - DOI